Cetera Trust Company N.A Invests $77,000 in OptimizeRx Co. (NASDAQ:OPRX)

Cetera Trust Company N.A acquired a new position in OptimizeRx Co. (NASDAQ:OPRX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 5,400 shares of the company’s stock, valued at approximately $77,000.

Other hedge funds also recently made changes to their positions in the company. Kennedy Capital Management LLC purchased a new position in shares of OptimizeRx in the third quarter worth approximately $4,323,000. AWM Investment Company Inc. increased its position in shares of OptimizeRx by 75.8% in the third quarter. AWM Investment Company Inc. now owns 782,571 shares of the company’s stock worth $6,088,000 after acquiring an additional 337,303 shares in the last quarter. Jacob Asset Management of New York LLC increased its position in shares of OptimizeRx by 30.1% in the third quarter. Jacob Asset Management of New York LLC now owns 370,330 shares of the company’s stock worth $2,881,000 after acquiring an additional 85,720 shares in the last quarter. Quadrature Capital Ltd purchased a new position in shares of OptimizeRx in the third quarter worth approximately $162,000. Finally, Jump Financial LLC purchased a new position in shares of OptimizeRx in the third quarter worth approximately $101,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Price Performance

OPRX stock opened at $9.09 on Tuesday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.04 and a current ratio of 3.04. The firm has a 50 day simple moving average of $13.11 and a 200 day simple moving average of $12.04. OptimizeRx Co. has a 52 week low of $6.92 and a 52 week high of $16.65.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Barclays assumed coverage on shares of OptimizeRx in a research report on Wednesday, January 3rd. They issued an “equal weight” rating and a $15.00 target price on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 target price on shares of OptimizeRx in a research report on Monday, April 1st. Stifel Nicolaus restated a “buy” rating and set a $13.00 price target on shares of OptimizeRx in a report on Monday, April 1st. Finally, JMP Securities restated a “market outperform” rating and set a $15.00 price target on shares of OptimizeRx in a report on Tuesday, April 16th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, OptimizeRx presently has an average rating of “Moderate Buy” and a consensus target price of $15.86.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.